“…Recently, promising results have been obtained with immunotherapy (monoclonal antibodies, e.g., ipilimumab), target therapy (BRAF inhibitors, e.g., vemurafenib; MEK inhibitors, e.g., cobimetinib), and combined treatments (BRAF inhibitors associated to MEK inhibitors, e.g., vemurafenib + cobimetinib) (Napolitano et al 2018;Schadendorf et al 2018). However, these treatments induce severe toxicity, including neutropenia, thrombocytopenia, fatigue, nausea, vomiting, and neurosensory troubles (Jang and Atkins 2014;Roos et al 2014;Lopatka et al 2018;Voskoboynik and Arkenau 2014). The wide range of antineoplastic treatments Electronic supplementary material The online version of this article (https://doi.org/10.1007/s43450-020-00036-2) contains supplementary material, which is available to authorized users.…”